TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent and to comply with the requirements of the protocol~* Diagnosis of RA for at least 6 months according to the revised 1987 ACR criteria for the classification of RA~* Positive serum RF~* Current treatment for RA on an outpatient basis~* Contact your local site that is listed for more inclusion criteria~Exclusion Criteria:~* Bone or joint surgery (including joint fusion) within 8 weeks prior to screening or joint surgery planned within 24 weeks after randomization~* Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty�s syndrome)~* Functional Class IV as defined by the ACR classification of functional status in RA~* History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic rheumatic disorders (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, overlap syndrome)~* Contact your local site that is listed for more exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Irbesartan and Atenolol in Hypertensive Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 ys old~* Male or female with no child bearing potential~* Seated blood pressure diastolic 90-115 mm Hg~* Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women~* Informed consent~Exclusion Criteria:~* Coronary artery disease, heart failure or other significant cardiac disorder~* Cerebrovascular accident within the past 6 months~* A seated systolic blood pressure above 200 mm Hg~* Significant renal disease, collagen or vascular disease, or gastrointestinal condition~* Significant allergy or intolerance to study drug~* Alcohol or drug abuse~* Uncontrolled diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Irbesartan (Type: EXPERIMENTAL): Irbesartan per os titrated to 300 mg od, 48 weeks
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol per os titrated to 100 mg od, 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Statin treatment for at least 3 weeks~* Reduced HDL: \< 40 mg/dL (1.03 mmol/L) in men or \< 50 mg/dL (1.29 mmol/L) in women~* Plus TWO of the following (thereby defining the patients to have metabolic syndrome (Grundy et al.; Circulation 2005)):~* Elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches) in women~* Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L~* Elevated blood pressure: ≥ 130 mmHg systolic blood pressure or ≥ 80 mmHg diastolic blood pressure or anti-hypertensive treatment~* Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated fasting glucose~Exclusion Criteria:~* Hypersensitivity to niacin~* Active liver disease or impaired liver function~* Persistent elevation of transaminases~* Cholestasis~* Gastric ulcer~* Acute coronary syndrome~* Gout~* Pregnancy, lactation~* Active infections~* Cancer~* Untreated concomitant diseases~* Renal insufficiency or renal failure~* Hypothyreosis~* Alcoholism~* Myopathies~* Muscle pain under therapy with fibrates or statins~* Hereditary muscle diseases in family history

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Extended-release Niacin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Uterotonic Prophylaxis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 20 wks 0 days gestation and 24 wks 0 days gestation~* English or Spanish speaking~* BP before injection 140/90 or below~* 18 years old or over~Exclusion criteria:~* hypertension either on the preoperative or operative day (defined as systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg)~* D\&E procedures with more than one day of cervical preparation with dilators~* use of protease inhibitors~* known coagulopathy~* known morbidly adherent placenta

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- methergine (Type: EXPERIMENTAL): Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
- saline placebo (Type: PLACEBO_COMPARATOR): Placebo group saline single injection when manual cervical dilation begins the day before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Food-Effect Pharmacokinetic Study of PL2200

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy normal male and female volunteers between 21 and 65 years of age.~Exclusion Criteria:~* Abnormal findings on physical examination or clinical laboratories, or significant medical history.~* Subject with hypersensitivity or contraindications to aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drug (NSAID).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PL2200 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a minimum of three consecutive pregnancy losses before 10 weeks gestation~* Positive lupus anticoagulant and/or anticardiolipin antibodies (IgG and IgM) on at least two occasions twelve weeks apart .~* Age between 19 - 37 years,~* Body mass index between 19-30~Exclusion Criteria:~* Parental chromosomal abnormalities~* Uterine abnormalities~* Luteal phase defect~* Systemic lupus erythematosus~* Previous thromboembolism~* Sensitivity to aspirin.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- enoxaparin 40 mg plus low dose aspirin (Type: EXPERIMENTAL): None
- Heparin calcium 5,000 U twice daily plus low dose aspirin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nepafenac Once Daily for Macular Edema - Study 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens;~* History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR) (mild, moderate, or severe) in the study eye;~* Best-corrected visual acuity (BCVA) of 73 letters or worse in the study eye with expectation of improvement after surgery;~* Understand and sign an informed consent document;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Pre-existing macular edema in the study eye;~* History in the study eye of retinal detachment, wet age-related macular degeneration, chronic or recurrent inflammatory eye disease, or prior procedures;~* Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study visit or through study exit;~* Planned multiple procedures for the study eye during the cataract/intraocular lens;~* Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids, as specified in protocol.~* Participation in any other clinical study within 30 days of the screening visit;~* Females of childbearing potential who are breast feeding, have a positive urine pregnancy test at screening, are not willing to undergo a urine pregnancy test upon entering or exiting the study, intend to become pregnant during the study, or do not agree to use adequate birth control methods for the duration of the study;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nepafenac (Type: EXPERIMENTAL): With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
- Vehicle (Type: PLACEBO_COMPARATOR): With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any age, but primarily infants 0-6 months.~* Children with confirmed diagnosis of congenital hyperinsulinism.~Exclusion Criteria:~* Cases in which surgery will not be considered by parents or guardians.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Subjects who had PET and surgery (Type: EXPERIMENTAL): Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and are candidates to be scheduled for surgery for partial pancreatectomy. Eligible children will undergo PET imaging with F-DOPA prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Comparison Of All FK-506 Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Renal transplant recipients, males or females, of 18 years of age or above.~2. Able to participate and willing to give written informed consent and to comply with study visits and restrictions.~3. Able to understand English.~4. Patients having received a primary or secondary renal transplant~Exclusion Criteria:~1. Evidence of acute rejection episode within the past three months prior to screening.~2. Recipients of organ transplants other than kidney.~3. Patients who are known to be HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prograf vs Envarsus XR vs Astagraf XL (Type: ACTIVE_COMPARATOR): Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
- Prograf vs Astagraf XL vs Envarsus XR (Type: ACTIVE_COMPARATOR): Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Healthy volunteers:~1. Male or female between 18 and 65 years old with a BMI of 18-32kg/m2~2. Must be in good health and not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study~CHB patients:~1. Male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2 and a minimum body weight of 45 kg~2. Must have chronic hepatitis B with no history of clinical decompensation~3. Seropositive for HIV, HCV, or HDV antibody at Screen~4. Previous treatment with any HBV antiviral treatments within the last 3 months~5. Other known cause of liver disease, including NASH

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ABI-H0731 or Matching Placebo (Type: EXPERIMENTAL): ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
- ABI-H0731 or Placebo and ETV or TDF (Type: EXPERIMENTAL): ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
- ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys (Type: EXPERIMENTAL): ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~* Age 18 years or older~* Histologically or cytologically proven adenocarcinoma of the breast~* Subjects who have locally recurrent or metastatic disease with at least one measurable lesion~* HER2 positive as determined by score of 3 on immunohistochemistry (IHC) staining or gene amplification by fluorescence in situ hybridization (FISH).~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0, 1 or 2~* At least 12 months since prior neoadjuvant or adjuvant chemotherapy~* At least 2 weeks since prior radiotherapy, endocrine therapy, trastuzumab, or lapatinib, with complete recovery from the effects of these interventions~* Adequate renal function~* Adequate bone marrow function~* Adequate liver function~* Adequate cardiac function~Key Exclusion criteria:~* Prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic HER2 breast cancer.~* Subjects who have had a prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer~* Prior exposure to greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than 720 mg/m2 epirubicin~* Inflammatory breast cancer~* Prior history of hypertensive crisis or hypertensive encephalopathy~* Clinically significant cardiovascular impairment~* Subjects with known central nervous system (CNS) disease are not eligible, except for those subjects with treated brain metastasis.~* Subjects with metastatic disease limited to bone are ineligible unless there is at least one lytic lesion with identifiable soft tissue components that can be evaluated by computed tomography (CT) or magnetic resonance imaging (MRI)~* Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen~* History of bleeding diasthesis~* Currently pregnant or breast-feeding.~* Subjects with preexisting Grade 3 or 4 neuropathy. Any peripheral neuropathy must recover to Grade less than or equal to 2 before enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide 9 mg Capsules in Active UC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men or women aged 18 to 75 years,~* Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology,~* Established disease,~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis,~* Toxic megacolon or fulminant colitis,~* Colon resection,~* Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile toxin in stool culture at screening),~* Malabsorption syndromes,~* Celiac disease,~* Bleeding hemorrhoids,~* Active peptic ulcer disease~* Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding,~* Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured,~* Any severe infectious disease (e.g., tuberculosis, AIDS),~* Severe co-morbidity substantially reducing life expectancy,~* History of colorectal cancer,~* History of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~- Healthy male or female subjects~Exclusion criteria:~- Any relevant deviation from healthy condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- FDC first, fasted (Type: EXPERIMENTAL): Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
- Single tablets first, fasted (Type: EXPERIMENTAL): single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
- FDC first, fed (Type: EXPERIMENTAL): Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
- Single tablets first, fed (Type: EXPERIMENTAL): single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lornoxicam vs. Paracetamol After Lower Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* lower abdominal surgery~Exclusion Criteria:~* body weight more than 150% of their ideal body weight~* history of significant cardiac, pulmonary, renal, hepatic or hematological disease; chronic drug or alcohol abuse; hypersensitivity to any of the studied drugs; bronchial asthma; gastritis or peptic ulcer; and pregnancy~* patients who received any analgesic drug a day before surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Lornoxicam (Type: EXPERIMENTAL): Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
- Control (Type: PLACEBO_COMPARATOR): Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
- Paracetamol (Type: EXPERIMENTAL): 1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete